Digital Performance for Employee Health & Wellbeing

B2B paid media must account for long buying cycles, multi-person buying committees, and the reality that a click rarely equals a customer. Optimization targets pipeline influence, not conversions. We manage B2B paid programs against downstream revenue metrics, not the cost-per-click vanity numbers that consumer marketers optimize for.

SEO builds the organic foundation that captures buyer research intent at every stage of the journey, from problem awareness through vendor evaluation and purchase decision. For B2B tech companies, SEO isn't just about rankings. It's about being present in the research process your buyers go through months before they ever talk to sales.

Traditional SEO optimizes for search engine rankings and click-through, while answer engine optimization ensures your content is cited by AI-powered discovery channels like ChatGPT, Perplexity, and Google AI Overviews. Both matter. SEO captures intentional searches, AEO captures the growing share of buyer research that happens through AI assistants.

CRO success in B2B is measured by pipeline generated per visitor, not just form submission rates, because a higher form fill rate means nothing if the leads don't convert to revenue. We track the full funnel from landing page to closed deal, testing changes that improve both volume and quality of pipeline contribution.

Marketing wellbeing technology to ROI-focused buyers requires leading with business outcomes (healthcare cost reduction, productivity gains, retention improvements) rather than engagement metrics that CFOs dismiss as soft. We build positioning that translates wellbeing outcomes into the financial language that budget holders understand, making your platform a business case rather than a nice-to-have.

The post-pandemic wellbeing market has shifted from "any investment is good" to "prove this actually works" as HR budgets face scrutiny and CEOs question whether wellbeing spend produces measurable returns. Companies that repositioned around clinical evidence, cost containment, and productivity impact are winning; those still marketing on participation rates are losing budget.